Background: The disease-modifying therapies (DMTs) largely used in multiple sclerosis (MS) may result in higher infectious risk.
Objective: We aimed to investigate the infectious risk in DMT-treated MS patients.
Methods: MS patients were evaluated for infectious risk before starting, switching or during DMT.